Literature DB >> 26595895

Craniotomy for cerebellar hemangioblastoma excision in a patient with von Hippel-Lindau disease complicated by uncontrolled hypertension due to pheochromocytoma.

Yoshifumi Mizobuchi1, Teruyoshi Kageji2, Yamaguchi Tadashi2, Shinji Nagahiro2.   

Abstract

INTRODUCTION: This report describes a patient with Von Hippel-Lindau (VHL) syndrome and uncontrolled hypertension due to pheochromocytoma who underwent craniotomy for the excision of a cerebellar hemangioblastoma combined with a laparoscopic adrenalectomy. CASE REPORT: A 31-year-old man presented with severe headache. MRI showed areas of abnormal enhancement in the left cerebellum that were determined to be hemangioblastoma with mass effect and obstructive hydrocephalus. His blood pressure rose abruptly and could not be controlled. CT of the abdomen revealed bilateral suprarenal tumors, and the patient was diagnosed as having VHL syndrome.On the third day, he presented with increasing headache, a decreased level of consciousness, and hemiparesis. We were not able to perform an craniotomy because abdominal compression in the prone or sitting position resulted in severe hypertension. We performed ventricular drainage to control his ICP. On the fifth day, we first performed a bilateral laparoscopic adrenalectomy to control ICP and then moved the patient to the prone position before performing a craniotomy to remove the left cerebellar hemangioblastoma. DISCU: ssion & conclusion In patients with pheochromocytoma, the effects of catecholamine oversecretion can cause significant perioperative morbidity and mortality, but these can be prevented by appropriate preoperative medical management. When carrying out an excision of cerebellar hemangioblastomas in patients with intracranial hypertension complicated by abnormal hypertension due to pheochromocytoma whose blood pressure is not sufficiently controlled, tumor resection of the pheochromocytoma prior to cerebellar hemangioblastoma excision in the same surgery may prevent increased ICP and reduce perioperative risk.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Hemangioblastoma; Pheochromocytoma; Von Hippel–Lindau disease

Year:  2015        PMID: 26595895      PMCID: PMC4701822          DOI: 10.1016/j.ijscr.2015.10.037

Source DB:  PubMed          Journal:  Int J Surg Case Rep        ISSN: 2210-2612


Introduction

Von Hippel–Lindau syndrome (VHL) is an autosomal, dominant, inherited familial cancer syndrome characterized by retinal and central nervous system (CNS) hemangioblastomas and cysts or tumors of the kidneys, adrenal glands, pancreas, epididymis, and endolymphatic sacs [1], [2], [3]. For patients with VHL who have confirmed or possible pheochromocytomas requiring resection of CNS tumors, preoperative alpha- and beta-adrenergic blockade is recommended to reduce the risk of perioperative hypertensive crisis [4]. However, there are no clear treatment guidelines for the excision of cerebellar hemangioblastomas in patients with intracranial hypertension complicated by abnormal hypertension due to pheochromocytoma whose blood pressure is not sufficiently controlled before surgery. This report describes a patient with VHL syndrome and uncontrolled hypertension due to pheochromocytoma who developed obstructive hydrocephalus and underwent craniotomy for the excision of a cerebellar hemangioblastoma combined with a laparoscopic adrenalectomy.

Case report

A 31-year-old man presented with a steady, gradually increasing, headache that had persisted for the previous 3 months. He was admitted to the emergency room of another hospital for a severe headache. His symptoms suggested intracranial hypertension. Magnetic resonance imaging (MRI) showed areas of abnormal enhancement in the left cerebellum, which were revealed to be a hemangioblastoma with mass effect causing obstructive hydrocephalus (Fig. 1). He was then referred to our hospital. On admission, his blood pressure and pulse rate were 220/120 mmHg and 110 bpm, respectively. His blood pressure rose abruptly following postural changes and mild abdominal compression. Fundus examination revealed a hemangioblastoma in the right eye, and neurological examination revealed truncal ataxia. Laboratory data showed increased levels of catecholamines and their metabolites in 24-h urine collection samples. Computed tomography (CT) of the abdomen revealed bilateral suprarenal tumors with a cyst and a 5-cm-diameter tumor in the left kidney (Fig. 2). The patient was diagnosed with VHL, and his severe headache and neurological symptoms suggested raised intracranial pressure (ICP). The day after admission, doxazosin mesilate treatment was started at a dosage of 8 mg/day to stabilize blood pressure. He was scheduled to undergo excision of a cerebellar hemangioblastoma after blood pressure was controlled with alpha- and beta-blockers.
Fig. 1

Axial (left) and sagittal (right) T1-weighted magnetic resonance images with gadolinium demonstrating a left cerebellar hemangioblastoma with a mural node causing obstructive hydrocephalus.

Fig. 2

Abdominal CT scan showing bilateral adrenal tumors (the right and left masses were 5.5 and 1.5 cm in diameter, respectively).

However, on the third day, he presented with an increasing headache, decreased level of consciousness, hemiparesis, and uncontrollable hypertension. Doxazosin mesilate was increased to 16 mg/day; however, we were unable to perform a craniotomy because of abdominal compression in the prone position. Similarly, mild stimulation of abdominal flexion in a sitting position induced very high blood pressure. Thus, we performed ventricular drainage to control ICP. After ventricular drainage, the patient’s consciousness level increased, and his headache was relieved. However, we judged that blood pressure stabilization by alpha-blockers would take time and that intraoperative blood pressure elevation by abdominal stimulation might result in intracranial pressure elevation either in the prone or sitting position. Moreover, there was concern that ICP control by ventricular drainage alone might further exacerbate the patient’s symptoms, causing upward herniation. On the fifth day, we decided to first perform a laparoscopic adrenalectomy on the patient in the supine position, considering the patient’s general condition and intraoperative and postoperative invasiveness, in order to excise the pheochromocytoma. After blood pressure was stabilized, the patient was shifted to the prone position to excise the cerebellar hemangioblastoma. We performed a bilateral laparoscopic adrenalectomy to control ICP by ventricular drainage. Intraoperatively, we administered propofol, remifentanil, phentolamine, landiolol, and a calcium blocker for blood pressure control, and the patient’s serum adrenaline level increased from 4885 pg/mL to 16,148 pg/mL (∼60–500 pg/mL). His blood pressure rose to 220 mmHg by mechanical stimulation when the tumor was compressed. However, after adrenalectomy, his serum adrenaline level decreased to 191 pg/mL, and the patient’s blood pressure returned to normal (Fig. 3). Next, we changed the patient to the prone position and performed a craniotomy to remove the right cerebellar hemangioblastoma. The patient’s neurological deficits were relieved postoperatively, no other deficits occurred, and no further hypertensive medication was required.
Fig. 3

Intraoperatively, we administered propofol, remifentanil, phentolamine, landiolol, and a calcium blocker to control blood pressure. At the times of intubation, skin incision, manipulation of the adrenal tumor, the patient’s blood pressure rose to 220 mmHg, and serum adrenaline level increased from 4885 pg/mL to 16,148  pg/mL (∼60–500 pg/mL). However, after adrenalectomy, serum adrenaline level decreased to 191 pg/mL, and blood pressure returned to normal.

Discussion

Hemangioblastoma can occur in any part of the CNS, but the sites of predilection are the posterior fossa (80%) and spinal cord (20%). Almost 95% of infratentorial hemangioblastoma are located in the cerebellum, mainly in the hemispheres and less frequently in the vermis [5]. Cerebellar hemangioblastoma are highly vascular but benign tumors that account for ∼2% of all intracranial tumors [6]. CNS hemangioblastomas occur in both type 1 (without pheochromocytoma) and type 2 (with pheochromocytoma) VHL [7]. Although they are benign, CNS hemangioblastomas may cause life-threatening complications and are a major cause of morbidity and mortality in VHL disease. It is estimated that VHL disease will be diagnosed in over 30% of patients with newly discovered cerebellar hemangioblastoma [8]. A total of 10–20% of patients with VHL harbor pheochromocytomas [9]. As a result, catecholamine oversecretion can cause significant perioperative morbidity and mortality. Early publications reported surgical mortality rates of 30–45%; however, with current medical management and new surgical techniques, the surgical mortality rate has been significantly improved to 0–2.9% [10], [11]. Therefore, it is recommended that all patients receive appropriate preoperative medical management to block the effects of circulating catecholamines [12], [13]. For patients with VHL who have confirmed or possible pheochromocytomas requiring CNS tumor resection, preoperative alpha- and beta-adrenergic blockade can be employed to reduce the risk of perioperative hypertensive crisis [4]. While patients’ outcomes following CNS hemangioblastoma has been generally good when atraumatic microsurgery is performed [14], [15], there are no clear treatment guidelines for the excision of cerebellar hemangioblastomas in patients with intracranial hypertension complicated by abnormal hypertension due to pheochromocytoma whose blood pressure is not sufficiently controlled before surgery. Goel et al. used propofol, sevoflurane, and an esmolol infusion and uneventfully used labetalol (0.1 mg/kg) to control hypertension and tachycardia during emergency craniotomy in a patient with VHL and pheochromocytoma [16]. However, when catecholamines are secreted by mild abdominal compression, thereby inducing hypertension and tachycardia as seen in our case, placing a patient in the prone or sitting position for cerebellar hemangioblastoma excision appears to introduce the possibility of uncontrolled ICP and tumor bleeding due to increase in blood pressure and the potential for intraoperative death due to uncontrolled hemodynamics. In relatively less invasive pheochromocytoma excision by laparoscopic cholecystectomy, blood pressure can be controlled with appropriate intraoperative medical management by experienced anesthesiologists, and the incidence of complications can be reduced to 0–2.9% with appropriate perioperative medical management [10]. Simultaneous tumor resection in which pheochromocytoma excision is first performed in the supine position, followed by cerebellar hemangioblastoma excision in the prone or sitting position, may prevent ICP elevation and reduce perioperative risk. In cases of craniotomy for cerebellar hemangioblastomas complicated by pheochromocytomas, simultaneous tumor resection may be a treatment option when there is good cooperation between urologists and anesthesiologists.

Conflict of interest

None

Funding

None

Ethical approval

None.

Consent

Obtained available for review if requested.

Author contribution

Study concept or design: Yoshifumi Mizobuchi, Shinji Nagahiro. Data collection: Teruyoshi Kageji, Tadashi Yamaguchi. Writing the paper: Yoshifumi Mizobuchi.

Gaurantor

Yoshifumi Mizobuchi.
  16 in total

1.  Surgical management of large solid hemangioblastomas of the posterior fossa.

Authors:  Jie-Qing Wan; Hua Cui; Yong Wang
Journal:  J Clin Neurosci       Date:  2011-01       Impact factor: 1.961

2.  Anesthesia for emergency craniotomy in a patient with von Hippel Lindau disease with pheochromocytoma.

Authors:  Sanjay Goel; Neerja Johar; Mary Abraham
Journal:  J Neurosurg Anesthesiol       Date:  2005-07       Impact factor: 3.956

Review 3.  Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease.

Authors:  S Richard; P David; K Marsot-Dupuch; S Giraud; C Béroud; F Resche
Journal:  Neurosurg Rev       Date:  2000-03       Impact factor: 3.042

4.  Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients.

Authors:  C Proye; D Thevenin; P Cecat; P Petillot; B Carnaille; P Verin; M Sautier; N Racadot
Journal:  Surgery       Date:  1989-12       Impact factor: 3.982

5.  Long-term outcome after resection of brainstem hemangioblastomas in von Hippel-Lindau disease.

Authors:  Joshua J Wind; Kamran D Bakhtian; Jennifer A Sweet; Gautam U Mehta; Jayesh P Thawani; Ashok R Asthagiri; Edward H Oldfield; Russell R Lonser
Journal:  J Neurosurg       Date:  2010-10-08       Impact factor: 5.115

Review 6.  Preoperative management of the pheochromocytoma patient.

Authors:  Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2007-11       Impact factor: 5.958

7.  Risk Factors for Hemodynamic Instability during Surgery for Pheochromocytoma.

Authors:  H Bruynzeel; R A Feelders; T H N Groenland; A H van den Meiracker; C H J van Eijck; J F Lange; W W de Herder; G Kazemier
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

8.  The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease.

Authors:  John E Wanebo; Russell R Lonser; Gladys M Glenn; Edward H Oldfield
Journal:  J Neurosurg       Date:  2003-01       Impact factor: 5.115

9.  Central nervous system lesions in von Hippel-Lindau syndrome.

Authors:  H P Neumann; H R Eggert; R Scheremet; M Schumacher; M Mohadjer; A K Wakhloo; B Volk; U Hettmannsperger; P Riegler; P Schollmeyer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

Review 10.  Massive hemorrhage in hemangioblastomas Literature review.

Authors:  Javier Ros de San Pedro; Fernando Alarcón Rodríguez; Belén Ferri Níguez; Juan F Martínez-Lage Sánchez; Antonio López López-Guerrero; Matías Felipe Murcia; Antonio M Ruíz-Espejo Vilar
Journal:  Neurosurg Rev       Date:  2010-01       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.